Australian researchers have launched a groundbreaking clinical trial targeting aggressive, previously untreatable cancers driven by the MYC protein. The trial, led by the Australian National University (ANU) and Canberra Health Services, will test a new drug called PMR-116, which disrupts MYC-driven cancer growth by blocking the cellular processes it activates, rather than the protein itself.
Using a “basket” trial approach, patients are grouped based on molecular biomarkers instead of cancer type, focusing on those with MYC-driven prostate, breast, ovarian, and blood cancers. Developed by ANU and Pimera Therapeutics, PMR-116 inhibits ribosomal biogenesis—a process hijacked by MYC in cancer cells.
The trial, supported by federal funding, will begin enrolling patients in Canberra, Melbourne, and Sydney in late 2025, especially those unresponsive to standard treatments. Researchers say the study could redefine global cancer treatment by shifting the focus from tumor location to molecular drivers, advancing precision oncology.
Credit : CGTN
You can listen to the programs organized by MI Radio on Google Podcast, Apple Podcast and Spotify.
You can download MI Radio application on Google Play Store and Apple App Store.
